BAF1598

antibody from Novus Biologicals

Targeting: IFNL1 IL-29, IL29

Western blot (Data presented on provider website)

Antibody Data

Product number

BAF1598

Provider

Novus Biologicals

Product name

Goat Polyclonal IL-29/IFN-lambda 1 Antibody

Antibody type

Polyclonal

Description

Antigen Affinity-purified. Detects human IL-29/IFN-lambda 1 in ELISAs and Western blots. In sandwich immunoassays, approximately 100% cross-reactivity with recombinant human (rh) IL-28B is observed, 35% cross-reactivity with rhIL-28A is observed and less than 0.2% cross-reactivity with rhIFN-alpha A, rhIFN-alpha B2, rhIFN-alpha G, rhIFN alpha I, and rhIFN-beta 1A is observed. In Western blots, approximately 25% cross-reactivity with rhIL-28A and rhIL-28B is observed.

Reactivity

Human

Host

Goat

Conjugate

Biotin

Isotype

IgG

Vial size

50 ug

Concentration

LYOPH

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.

References

Submitted references

High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus.

Oke V, Gunnarsson I, Dorschner J, Eketjäll S, Zickert A, Niewold TB, Svenungsson E
Arthritis research & therapy 2019 Apr 29;21(1):107

---

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE).

Oke V, Brauner S, Larsson A, Gustafsson J, Zickert A, Gunnarsson I, Svenungsson E
Arthritis research & therapy 2017 Jun 15;19(1):139

---

Interferon (IFN)-λ is a potential mediator in lupus nephritis.

Zickert A, Oke V, Parodis I, Svenungsson E, Sundström Y, Gunnarsson I
Lupus science & medicine 2016;3(1):e000170

---

Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses.

Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, Picard C, von Bernuth H, Senechal B, Plancoulaine S, Al-Hajjar S, Al-Ghonaium A, Maródi L, Davidson D, Speert D, Roifman C, Garty BZ, Ozinsky A, Barrat FJ, Coffman RL, Miller RL, Li X, Lebon P, Rodriguez-Gallego C, Chapel H, Geissmann F, Jouanguy E, Casanova JL
Immunity 2005 Nov;23(5):465-78